Incretins Update: A Holistic Approach to Patients With Type 2 Diabetes and Cardiometabolic Comorbidities

Medical Minute 2: Multisystemic Actions of GIP/GLP-1 Coagonists
Download All
In this series of concise Medical Minute videos and ClinicalThought™ commentaries, expert faculty review the actions and clinical applications of current and emerging incretin-based therapies for persons with type 2 diabetes.
Carol Hatch Wysham, MD

Clinical Trial Results of GIP/GLP-1 Coagonists

In this concise Medical Minute video, gain expert insights on the clinical trial data supporting the use of tirzepatide to improve outcomes in persons with T2D.

Carol Hatch Wysham, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Registered Dietitians/Dietetic Technicians, Registered: maximum of 0.25 CPEU(s) Released: September 2, 2021 Expired: September 1, 2022

Gain expert insights on the clinical trial data supporting the use of tirzepatide to improve outcomes in persons with T2D.

Carol Hatch Wysham, MD Released: September 2, 2021

The dual GIP/GLP-1 receptor agonist has demonstrated efficacy in lowering A1C and body weight in the phase III SURPASS trials. Here’s my take on how it may fit into the treatment toolbox for type 2 diabetes.

Carol Hatch Wysham, MD Released: September 21, 2021
Provided by Clinical Care Options
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Endocrine Society Logo
Supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings